Tag: spetspatient

  • Why are patients the only ones around the table expected to work for free?

    Why are patients the only ones around the table expected to work for free?

    (Detta inlägg finns även på svenska: LÄNK)

    (This post is complemented with a checklist: LINK)

    I have been part of literally hundreds of conversations and meetings with researchers, healthcare professionals, companies, agencies, conference organizers and others wanting to involve patients. Here, I have listed 12 arguments that I have heard when asking if the offer comes with some form of payment (plus one bonus argument, which I think is the true reason that patients are often expected to work for free)

    First, let’s make sure that we’re talking about the same thing:

    Primary or secondary patient involvement?

    When I teach or present on patient involvement, I always spend some time at the start to ensure that we all agree on what we’re talking about. If the topic is how to engage patients in participating in research studies or clinical trials, I refer to it as primary patient engagement. For conversations on getting patient input on the structure and/or process of studies or trials to improve them for upcoming participants, I use the term secondary patient engagement. I have written about this before => link to post.

    Many regulatory bodies, research funders, governmental authorities and others all around the world are increasingly promoting, encouraging, and even demanding secondary patient engagement for applications and projects. And that is what this post is about: secondary patient engagement.

    I want to point out that the same principles apply to engaging patients to help improving healthcare processes or facilities, medtech products, evaluating research applications, speaking at conferences etc.

    Here we go, 12 arguments I’ve heard on why not to pay patients:

    (edit: now with five additional arguments, based on comments and feedback, between reasons 12 and 13)

    Reason 1: “This is voluntary engagement, not work”

    Imagine a project meeting where a researcher, a clinician, a project manager—and a patient—are all invited to help improve a study design. The meeting has an agenda, background material is sent out in advance, and everyone is expected to read it, think it through, and contribute informed input.

    The researcher, clinician, and project manager are all attending as part of their paid workday. The patient is described as “volunteering.”

    Yet the expectations are the same: show up on time, be prepared, share expertise, and help shape decisions the project depends on. The only real difference is how the contribution is labeled—and whether it is compensated.

    How can this argument be met?

    Counterarguments

    • The tasks are defined, scheduled, and requested by the organization → this is work.
    • Volunteering is initiated by the individual. Here, the system initiates.
    • This is organized knowledge work, not volunteering.

    Reason 2: “Compensation threatens independence”

    Imagine the same meeting where everyone is paid for their time—except the patient, who is told that payment might make their input less independent. The implication is that being unpaid makes their perspective more trustworthy. Strangely enough though, the paid professionals’ independence is never questioned.

    Counterarguments

    • Everyone else in the room is paid without their independence being questioned.
    • Transparency about compensation increases credibility.
    • Independence is secured by transparency, not by lack of payment.

    Reason 3: “But researchers (doctors, nurses, etc) do this (review funding applications, sit on advisory boards, present at conferences, etc) without payment”

    No, they don’t. This argument overlooks that these activities usually take place within paid employment, during salaried work hours, and contribute to professional merit, networks, and career progression. What appears as “unpaid” is in fact embedded in a system where time, status, and long-term benefit are already compensated. Patients, in contrast, are expected to contribute outside any such structure.

    Counterarguments

    • For professionals, this work happens within paid roles and paid time; for patients, it does not.
    • These activities build careers and merit for professionals—patients receive no equivalent benefit.
    • What looks unpaid for staff is still supported by salary, status, and infrastructure; patients stand outside all three.

    Reason 4: “There’s no budget for paying patients”

    Another type of argument relates to financial aspects. It is often said that compensation simply wasn’t planned for, as if budgets were fixed facts rather than reflections of priorities. Yet the same project easily finds funds for venues, catering, consultants, and staff time—which simply means that the real issue is not lack of money. It’s about what the organization sees as important.

    Counterarguments

    • Budget reflects priorities, not constraints of nature.
    • The same budgets accommodate consultants and communication activities.
    • If it is not in the budget, it is because it was deprioritized.

    Reason 5: “It’s so administratively complicated”

    This argument points to practical hurdles—tax forms, payment systems, insurance, procurement rules—as if these were insurmountable barriers. But the very same administrative machinery routinely handles fees for consultants, speakers, and external experts. What it reveals is not true complexity, but that the system was never designed with patients in mind as formal contributors.

    Counterarguments

    • The system already manages consultant fees and honoraria.
    • “Complicated” means the organization has not adapted to patients as contributors.
    • Administrative systems should adapt to reality, not the other way around.

    Reason 6: “We don’t want to create ‘professional patients’”

    This argument reflects a concern that some patients might become too experienced, too familiar with research and healthcare processes, and therefore somehow less “authentic.” The strange thing is that in every other context, growing competence and repeated involvement are seen as assets that improve quality. What is framed as a risk here is, in practice, the very process by which expertise is developed.

    Counterarguments

    • What is being described is competence development.
    • We do not question “professional researchers”.
    • Competent patients are an asset, not a threat.

    Reason 7: “We are giving patients a chance to contribute to research / future patients / their own community”

    This frames participation as a gift to the patient rather than a contribution to the project. It suggests that the opportunity to be involved is itself a form of compensation, shifting attention away from the value the patient adds. In doing so, requested work is seen as a favor granted, rather than expertise sought.

    Counterarguments

    • Being invited is not compensation when real work and expertise are requested.
    • Calling it a “chance to contribute” reframes sought-after expertise as a favor instead of a contribution.
    • It is frankly unethical to try to shame patients, who often are struggling with illness, worry and financial hardship, into contributing for free.

    Reason 8: “Patients benefit from participating”

    This is an especially infuriating argument, that patients should not be paid because they get benefit from their contributions in the form of strengthening of health and motivation. This argument suggests that any personal health gains a patient might experience from being involved somehow replace the need for compensation. It implies that improved understanding, empowerment, or a sense of purpose is “payment enough.” By that logic, however, no one whose work is meaningful, educational, or professionally rewarding would ever need a salary.

    Counterarguments

    • Researchers also benefit personally from salary and career advancement. So, by the same logic, they should also not get paid.
    • Personal benefit does not negate that something is work.
    • Self-interest does not disqualify work—otherwise no one would be paid.

    Reason 9: “Compensation could attract the ‘wrong kind of patients’”

    This argument assumes that financial motivation makes participation less genuine, as if only those who can afford to contribute for free are the “right” voices. In practice, it means that unpaid involvement filters out anyone without spare time or financial flexibility. Rather than protecting quality, it quietly ensures that only the most privileged patients are able to take part.

    Counterarguments

    • This argument is never applied to professionals.
    • Compensation enables participation from those who otherwise cannot afford it.
    • Without compensation, you only recruit the economically privileged.

    Reason 10: “Patients don’t know enough about what we do for us to pay them”

    This argument suggests that patients lack the technical understanding required to warrant compensation, as if payment were reserved only for formal expertise. Yet patients are invited precisely because they bring a different kind of knowledge—about living with a condition, navigating care, and seeing gaps professionals may overlook. Dismissing this as insufficient knowledge overlooks the very reason they were asked to contribute in the first place.

    Counterarguments

    • Patients are invited for what they know that professionals don’t—not for what they lack.
    • You’re compensating contribution and time, not academic credentials.
    • If their knowledge isn’t valuable, they shouldn’t be in the room in the first place.

    Reason 11: “We’ve never paid patients before”

    This argument rests on tradition: it has always been done this way, so it feels natural to keep doing it. But history mostly tells us how things used to work—not whether they still make sense. Many of the improvements in patient involvement have come from challenging exactly these old routines.

    Counterarguments

    • Tradition is not an argument in knowledge development.
    • Patient involvement as a field exists precisely to change past practice.
    • Historical practice is the reason patient knowledge has been underused.

    Reason 12: “Not all patients want to get paid” or “Not all patients are able to accept payment”

    This argument points out that some patients prefer to contribute without compensation, or may be restricted by benefit rules or employment status. While this may certainly be true for some individuals, it turns a personal choice into a general rule for everyone. The fact that a few people are willing—or forced—to work for free does not mean that unpaid work should be the norm.

    Counterarguments

    • Individual preference should not define the norm for everyone else.
    • The option to decline payment is fair; the absence of payment is not.
    • Basing the system on who can afford to work for free excludes those who can’t.

    These additional reasons have been added as a result of comments and feedback:

    Additional reason 1: “We can’t pay you, but you’ll get great connections by speaking at our conference”

    This frames visibility and networking as a substitute for compensation. It assumes that exposure, contacts, or prestige are adequate payment for preparation time, travel, and sharing expertise. In practice, it mirrors a pattern where patients are expected to trade real work for intangible benefits that primarily serve the organizer.

    Counterarguments

    • Exposure and networking do not replace compensation for time and expertise.
    • Professionals invited to speak are rarely asked to accept “connections” instead of payment.
    • If the talk creates value for the conference, it deserves proper compensation

    Additional reason 2: “We can’t pay you, but you can use our app/AI bot/system for free”

    This argument reframes access to a product or service as a form of compensation. It treats the patient’s time and expertise as something that can be exchanged for exposure, testing access, or early use of a tool. In reality, this shifts the relationship from collaboration to unpaid product testing, where the patient’s contribution creates value for the company or project without any financial recognition.

    Counterarguments

    • Access to a product is not compensation for professional input and time.
    • This turns patient involvement into unpaid user testing.
    • If the tool has real value, it should be offered in addition to fair compensation—not instead of it.

    Additional reason 3: “We can’t pay you, but why don’t you fundraise to cover your own costs and then contribute for free?”

    This argument asks the patient to take on the financial responsibility for enabling their own participation, while everyone else is paid from the project’s budget. It turns involvement into a personal funding problem and shifts the burden of resourcing the project onto the very person whose knowledge is being requested.

    Counterarguments

    • Asking someone to fundraise to work for free reverses who is responsible for resourcing the project.
    • No other contributor is expected to secure their own funding to be allowed to participate.
    • If the contribution is important enough to ask for, it is important enough to budget for.

    Additional reason 4: “We’d love to pay you – but how?” (followed by silence)

    This starts as apparent goodwill: praise for your contribution and an expressed intention to compensate you. You provide the requested invoice or details—and then nothing happens. Months pass. A year later, you’re warmly invited back because your previous input was “so valuable,” while the earlier payment is still unresolved.

    Counterarguments

    • Good intentions without follow-through are functionally the same as not paying.
    • If an organization can manage contracts and payments for others, it can do the same for patients.
    • Unpaid past work should be resolved before new involvement is requested.

    Additional reason 5: “If you won’t do it, we will find someone else who will”

    This argument relies on the fact that some patients, out of goodwill, passion, or necessity, are still willing to contribute for free. It shifts the focus from fairness to replaceability, implying that the issue is not the value of the contribution but the willingness of someone to accept unpaid work.

    Counterarguments

    • The availability of unpaid contributors does not make unpaid work ethical.
    • Replaceability does not reduce the value of the contribution.
    • This approach selects for who can afford to work for free, not for who is best suited to contribute.

    Reason 13: The unspoken underlying argument

    The real, unspoken argument is probably:

    “If we start paying patients, we acknowledge that their knowledge is work. And that challenges the existing knowledge hierarchy”

    This is not about money. It is about epistemic status.

    Counterarguments

    • Yes — that is the point.
    • If patients contribute to knowledge production, they are knowledge actors.
    • Compensation is an organizational recognition of this.

    This is about how we view knowledge, not about money.

    Here is an argument that can be used to close:

    Either this is a real contribution to research and healthcare improvement — and should be compensated.
    Or it is symbolic participation — and we should be honest about that.

    Which ones have you heard? Have you heard any other arguments for not paying patients? Let me know in the comments.

  • A problem to be solved or a life to be lived?

    A problem to be solved or a life to be lived?

    A while back, I had two different meetings on the same day. They were different in so many ways but at the same time, they were also similar. In the first meeting, I was discussing ways that AI can be used for persons living with Parkinson’s disease (PD) with researchers in medicine and technology. The second meeting was with researchers in philosophy and history of science. We were also discussing the possibilities of AI for people living with different forms of disabilities and PD was one of the examples.

    (more…)
  • Managing medication in PD – both complex and simple?

    Managing medication in PD – both complex and simple?

    Medication management is probably the absolutely most important part of my Parkinson’s disease (PD) selfcare since without my pills, my body would not function. During the day I take meds approximately every three hours to be able to move around, take care of myself and be able to work. When I wake up in the morning, I have not taken any meds for at least 7 hours and my movements are REALLY slow and stiff.

    My approach to PD is that I try to take my meds at the same times every day. I know that other persons with Parkinson’s (PwP) have other approaches and no-one really knows which approach is best, since there has been no research conducted (or at least not published) comparing different approaches (which is actually one of my main reasons for writing this post).

    When I occasionally make changes to my medication regime, I note down dates of the change and what I changed (for example types of meds added/taken away, changes in timings for intakes, and/or changes in combinations of meds for each intake). For example, a few months ago I noticed that I tended to get slightly dyskinetic (a side effect of PD meds, see here) around lunch so I decided to push my second dose of meds 30 minutes and started taking it at 10:00 am instead of 9:30 am. This changed resolved my dyskinesia. These notes are for myself, none of my neurologists have ever asked about changes I have made between visits, they have only shown an interest in my current regimen at the time of the visit. I can completely understand this, they have enough work to do as it is and don’t need more tasks to complete. Of course there is plenty that could be learned from systematically recording individual medication regimes for a large number of persons with Parkinson’s (PwP) including following up the effects of that regimen on an individual level but I have long since accepted that that is probably not the best use of healthcare resources.

    In my role as an academic researcher, I have applied for funding many times over the past decade to address different aspects of how to optimise PD meds on an individual level. Unfortunately my funding applications have not really succeeded despite the fact that this area is extremely under-researched. I think there are several reasons for this apparent disinterest in the field of medication optimisation in PD and I will mention the three at the top of my mind:

    1. Complexity

    PD is SUPER COMPLEX! We have heard this so many times but what does it actually mean? The complexity of PD is multi-layered and there is so much we currently don’t know. We don’t know how and why the condition starts on an individual level, we are not sure about what processes makes the condition progress, and we don’t know why some medications work well for some but do not work as well for others.

    On the level of individual neurologists, I think that many of the clinicians who have made it their profession to help us actually think that medication intakes are already optimized based on available guidelines and their clinical experience. Those guidelines are however based on group-level data, and do not often translate well to individual patients. There is a huge gap between what is measured in research trials (which subsequently forms the basis of guidelines) and what PwP experience in their daily lives.

    One aspect that is often overlooked is that taking medication is not as simple as just swallowing a pill at the right time. It requires remembering (which, ironically, can be difficult when you have a neurodegenerative disease), carrying medication with you at all times, for some PwP also planning around meals, and adjusting for unpredictable factors such as stress, sleep quality, and physical activity. Even something as basic as getting water to take a pill can be a challenge in certain situations. The effort required to consistently take PD medication is far greater than many neurologists or researchers realize.

    Another factor adding to the complexity is that we living with PD are not really interested in taking the pills, we actually have zero interest in the actual pill taking itself. The reason we take them is to get the effect the pills (hopefully) have on reducing our symptoms. But what does healthcare use to evaluate this process? They use medication adherence, meaning if we take our pills in the way our neurologists have prescribed. As far as I know, there are no standardized adherence scales available that take into account the complexity of finding your individual best timings for intakes of meds to achieve the optimal effect.

    And since this complexity doesn’t directly influence the work of neurologists and researchers, it’s not strange that they don’t see the need for research into how to best optimize PD meds.

    2. Money

    The reality is that the use (and non-use) of pharmaceuticals is (almost) entirely driven by money. And currently there is no money to be gained on a corporate level from helping the approximately 10 million PwP in the world getting a better effect from the many pills we take.

    The pharmaceutical industry mostly hinges on developing new drugs, not on optimizing the use of existing ones. This means that the funding available for research favor the discovery of new molecules over the fine-tuning of treatment regimens for individual patients.

    3. Simplicity

    As a person who has spent more time thinking about this A LOT over the past 10 – 15 years, probably more than is healthy…, I have come to the conclusion that the main problem with the issue of medication optimization in PD actually is simplicity. More precisely, the illusion of simplicity. Medication adherence and effectiveness in PD are mostly treated as simple, binary issues: “Did you take your medication? Yes or no?” But in reality, it’s much more complex. Timing, food intake, stress levels, sleep quality, and countless other factors can influence how well our meds works.

    Yet, our healthcare system is not set up to systematically track and adjust for these variables. Instead, PwP are mostly left to figure it out themselves, with trial and error as our primary tool.This means that many PwP, myself included, spend years fine-tuning our medication regimens without structured support. Some of us get lucky and find a pattern that works well; others struggle for years with inconsistent results.

    In conclusion

    For this area to develop, we need a better understanding of how PwP actually take their medication in daily life and not just how they are prescribed to take it. We need more research that focuses on the real-world challenges of medication adherence, from remembering doses to managing side effects and adjusting for the unpredictability of daily life with PD. We need a more nuanced discussion of what is working, what isn’t, and why. Until then, PwP will continue doing what we have always done: adapting, experimenting, and trying to make the best of an imperfect system.

    It’s ironic that while Parkinson’s medication is one of the most researched aspects of the disease, the actual experience of taking it—the daily struggles, the trial and error, the constant balancing act—is still largely unstudied. The truth is, many PwP are experts in managing their own meds out of necessity, yet our knowledge remains anecdotal and undervalued in clinical settings. If we truly want to improve Parkinson’s care, we need to start acknowledging the experiential expertise of us who live with it every single day.

    And no, there is nothing simple about managing PD meds – it’s complex all the way!

  • Nej, vi är INTE alla patienter!

    Nej, vi är INTE alla patienter!

    Idag medverkade jag i en panel på en digital konferens om den svenska life sciencestrategin och hur arbetet kan/bör/ska fortgå framåt för att “kraftsamla och göra verkstad” med “patientnytta i fokus”. (OBS: min användning av citattecken är inte ironiskt menad, det är faktiska citat från konferensen.) Jag har medverkat i rådgivande grupper på departementsnivå sedan 2014 och har sett området life science bli tydligare definierat under denna tid, vilket är glädjande för detta är ett väldigt viktigt område. Patientperspektivet har under denna tid fått en alltmer tydlig plats i diskussionerna och i strategidokumenten, se till exempel den senaste life sciencestrategin HÄR.

    Det var en bra konferens med intressanta diskussioner och perspektiv. Men… under den avslutande panelen så var det en person som gjorde en kommentar. Jag har hört samma sak många gånger förut och jag trodde att vi hade kommit längre. Han sa:

    …vi är ju alla patienter…”

    Och på ett sätt har han rätt: vi får alla någon gång hjälp från vården och är därmed alla någon gång i våra liv patienter. Det är dock stor skillnad på att behöva läkemedel någon gång ibland, kanske en kur antibiotika vart tredje år eller så, och att vara helt beroende av läkemedel för att kroppen ska fungera. Om jag inte hade tillgång till mina mediciner, fem olika receptbelagda läkemedel som jag tar i olika kombinationer vid sex olika tillfällen varje dag, så skulle jag inte kunna arbeta. Jag skulle inte heller kunna ta hand om mig själv, göra hushållssysslor, klä på mig själv eller sköta min egen hygien. Innan levodopapreparaten blev tillgängliga under 1960-talet så var Parkinson en sjukdom som man dog av inom max 10-15 år.

    Alltså, kära life science-sektorn: nej, vi är inte alla patienter. Om ni verkligen vill förbättra kliniska prövningar, nyttiggörandet av hälsodata, ansvarsfull policyutveckling, teknik för ökad hälsa och de andra ambitionerna i life sciencestrategin, då får ni inte bäst hjälp av någon medelålders mellanchef som behöver bli frisk från halsflussen i tid till Vasaloppets Öppet spår. Nej, den bästa hjälpen får ni från någon som vet hur hjälplös man är när läkemedlet man behöver är restnoterat med okänd leveranstid, någon som vet hur icke-sömlöst vårt svenska vårdsystem är, någon som vet hur väldigt många stolar det finns som man kan falla mellan.

    Kort sagt, ni behöver hjälp av en patient!

  • Uppdatering av Helsingforsdeklarationen

    Uppdatering av Helsingforsdeklarationen

    Visst känner du till Helsingforsdeklarationen? Den antogs första gången för 60 år sedan av World Medical Association (WMA) och fastslår ett antal etiska principer att beakta i medicinsk forskning. Helsingforsdeklarationen är inte juridiskt bindande men har haft stor inverkan på lagstiftning och regelverk i hela världen, inte minst i Sverige.

    I samband med WMA:s 75:e General Assembly i oktober 2024 så fastslogs även en uppdatering av Helsingforsdeklarationen med en rad viktiga förändringar, se länk till hela den uppdaterade deklarationen här.

    Den allra viktigaste förändringen är att man genom hela dokumentet ändrat ordet “subjects” till “participants”. Detta utgör en omvälvande förändring i synen på de som deltar i forskningen. En person som är “research subject” blir studerad och har en passiv roll medan en “research participant” kan ha en mer aktiv roll i forskningen. WMA anger själva att förändringen gjorts för att på ett tydligare sätt visa att man som forskare måste respektera rättigheterna hos personerna som medverkar i forskningen och visa hur viktiga de är.

    En annan viktig förändring är att man ändrat från att använda uttrycket “vulnerable groups and individuals” till att istället skriva “individual, group, and community vulnerability”. Det kanske kan verka som hårklyverier men denna förändring signalerar en mycket viktig perspektivförflyttning. Den tidigare formuleringen innebar att sårbarheten på sätt och vis sågs som en egenskap som grupper eller individer har, vilket blir olyckligt. Med den nya formuleringen vill WMA signalera att sårbarhet inte är statisk utan i hög grad föränderlig och till stor del beror av sammanhanget man just då befinner sig i.

    Den tredje förändringen jag vill nämna är ett helt nyskrivet stycke som lagts till i denna version. På engelska står det i paragraf 6, tredje stycket:

    Meaningful engagement with potential and enrolled participants and their communities should occur before, during, and following medical research. Researchers should enable potential and enrolled participants and their communities to share their priorities and values; to participate in research design, implementation, and other relevant activities; and to engage in understanding and disseminating results.

    Jag har tillsammans med ChatGPT gjort en översättning/bearbetning:

    Före, under och efter att medicinsk forskning genomförs så bör potentiella och registrerade deltagare samt deras föreningar, organisationer eller nätverk ges möjlighet till medverkan med mening (min översättning/tolkning av “meaningful engagement”). Forskare bör möjliggöra för potentiella och registrerade deltagare samt deras föreningar, organisationer eller nätverk att dela med sig av sina prioriteringar och värderingar, delta i forskningsdesign, genomförande och andra relevanta aktiviteter samt engagera sig i att förstå och sprida resultat.

    Dessa förändringar är för mig en tydlig signal om att vår gemensamma syn på medicinsk forskning och dess roll i världen håller på att förändras. Jag gläds åt den stärkta synen på patienter och forskningsdeltagare som detta förmedlar.

    På vilket sätt kommer den nya versionen av Helsingforsdeklarationen förändra din forskning?

    Länkar till relevanta dokument:

    Den uppdaterade Helsingforsdeklarationen (på engelska)


  • “Vill du dricka cappuccino eller vill du bli frisk?”

    “Vill du dricka cappuccino eller vill du bli frisk?”

    I vården pratar man ibland om “delat beslutsfattande” (shared decision-making på engelska). Det innebär enligt en rapport från SKR (länk): “Delat beslutsfattande eller shared decision making är ett arbetssätt för att öka individers delaktighet i vården och omsorgen. Metoden hjälper personen att ta en aktiv roll i beslut om den egna hälsan och om behov av vård och stöd”.

    Delat beslutsfattande inom vården nämndes först i vetenskaplig litteratur under 1970-talet, men den huvudsakliga utvecklingen inom området har ägt rum efter 1997, när den välciterade artikeln “Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango)” publicerades. I den skriver författarna att “konceptet har hittills varit ganska otydligt definierat” och föreslår att följande fyra beståndsdelar är avgörande för delat beslutsfattande: (1) att minst två deltagare – läkare och patient – är involverade; (2) att båda parter delar information; (3) att båda parter tar steg för att bygga en samsyn om behandlingen; och (4) att en överenskommelse nås om den behandling som ska genomföras.

    Sedan dess har många tusentals vetenskapliga studier genomförts för att öka vår förståelse för vad som gör att delat beslutsfattande fungerar eller inte, och de senaste åren har flera tusen artiklar publicerats varje år. I olika länder har riktlinjer och rekommendationer utvecklats med syfte att stötta ett effektivt delat beslutsfattande och en viktig aspekt är att patientens värderingar och preferenser ska tydligt ingå i beslutsprocessen. Detta är såklart extra viktigt när själva genomförandet av den behandling eller åtgärd som ska beslutas ligger helt i patientens händer. Vilket, om vi ska vara ärliga, faktiskt är fallet för de allra flesta behandlingar inom vården idag.

    Därför blir jag alltid förvånad när jag träffar vårdpersonal som inte verkar förstå att vi som patienter faktiskt nästan alltid har möjlighet att använda vårt veto i behandlingsbeslut. Jag vill nämna två exempel som jag nyligen upplevt. I det första exemplet var jag i samtal med en primärvårdsläkare. Trots att mitt hjärta, enligt de tester den läkaren hade beställt, inte visade några tecken på sjukdom, ville hen skriva ut betablockerare till mig. Jag frågade vilka de vanligaste biverkningarna är och hen sa att eftersom den önskade effekten av betablockerarna är att sänka hjärtfrekvensen för att förhoppningsvis minska antalet extra slag, så är en vanlig biverkan ökad trötthet. Detta gjorde mig lite fundersam och jag sa att jag inte behöver ännu mer trötthet i mitt vardagsliv, jag får redan mer än tillräckligt från min Parkinsons sjukdom. Jag frågade vilka de viktigaste fördelarna skulle vara för mig med att ta betablockerare. Istället för att då fortsätta denna konversation i den asynkrona chatt som min vårdcentral erbjuder, plockade hen upp sin telefon och ringde mig. Hen svarade inte på min fråga om de viktigaste fördelarna, istället upprepade hen sin rekommendation för mig att börja med betablockerare och att: “man kan också dö av plötsligt hjärtstillestånd”.

    Det andra exemplet är från en diskussion jag hade med en vårdgivare angående möjliga livsstilsförändringar bland annat förändringar i kosten. Vi diskuterade olika alternativ och jag fick intrycket att personen hade vissa personliga övertygelser om vad hen trodde skulle vara bäst för mig. Detta eskalerade när diskussionen gick över till olika typer av mjölk (ko-/havre-/soja-/etc) och hen verkade tycka att alla typer av mjölk borde undvikas. Jag frågade vilken typ av mjölk jag då skulle använda till cappuccino och hens svar blev: “vill du dricka cappuccino eller vill du bli frisk?”.

    Missförstå mig inte, jag är fullt medveten om att det är möjligt att båda dessa vårdgivare har helt rätt i sina uttalanden. Jag kan mycket väl drabbas av plötsligt hjärtstillestånd och det är fullt möjligt att min hälsa skulle gynnas av att utesluta alla sorters mjölk från min kost. Min poäng är dock att om de inte tar mina frågor på allvar så kan de inte vara säkra på att jag kommer att följa deras rekommendationer. Jag skulle vilja hävda att en av de viktigaste “valutorna” inom hälsa och vård är förtroende som dessutom är ömsesidigt. Detta förtroende är en färskvara som måste vårdas kontinuerligt. En god vård bygger på ömsesidigt förtroende och respekt för patientens preferenser och värderingar i beslutsfattandet.